Targeted radiation therapy illustration

SBRT: Revolutionizing Cancer Treatment?

Soraya Malik in Health & Wellness December 2025 • 4 min read.

"Unpacking the Latest Advances in Stereotactic Body Radiation Therapy for Lung and Prostate Cancer"

Stereotactic Body Radiation Therapy (SBRT) has emerged as a significant advancement in cancer treatment, offering a precise and effective approach to targeting tumors while minimizing damage to surrounding healthy tissues. This technique is particularly valuable for patients with localized tumors who may not be suitable candidates for surgery or prefer a non-invasive treatment option.

Two key areas where SBRT has shown considerable promise are in the treatment of lung and prostate cancer. In lung cancer, SBRT is used for both primary early-stage non-small cell lung cancer (NSCLC) and local relapses following surgery. For prostate cancer, SBRT offers an alternative to traditional radiation therapy, with the goal of delivering high doses of radiation to the tumor while sparing the rectum and other nearby organs.

This article will explore the latest research on SBRT for lung and prostate cancer, highlighting the benefits, challenges, and ongoing efforts to optimize treatment protocols. We will delve into the importance of credentialing in lung SBRT, as well as the dosimetric considerations for achieving optimal rectal sparing in prostate cancer SBRT. Understanding these aspects is crucial for healthcare professionals and patients alike, as SBRT continues to evolve and play an increasingly important role in cancer management.

Lung SBRT: Credentialing and Consistency in Treatment Delivery

A study was conducted in Canada to assess the variability in lung SBRT practice among different centers. The OCOG-LUSTRE trial (NCT01968941) compared SBRT to conventionally hypofractionated radiation for stage I medically inoperable NSCLC. A key component of this trial was a comprehensive credentialing process aimed at ensuring consistent and high-quality treatment delivery across all participating centers.

The credentialing process involved 15 Canadian centers, some with prior SBRT experience and others without. Each center had to meet specific requirements to demonstrate their ability to safely and effectively deliver SBRT. These requirements included:

Completing an institutional survey detailing treatment protocols, dosimetry practices, and image guidance equipment.
Demonstrating acceptable delivery accuracy using the Imaging and Radiation Oncology Core (IROC) thoracic phantom.
Successfully contouring and completing standardized test cases for both central and peripheral NSCLC tumors.

The results of the credentialing process revealed that while all centers successfully completed the surveys and phantom testing, there were notable variations in contouring accuracy. Specifically, the distance between corresponding contours was highest for the brachial plexus in central cases and for vessels in peripheral cases. These findings highlight the importance of standardized training and quality assurance measures to minimize variability and ensure consistent treatment delivery in lung SBRT.

The Future of SBRT: Balancing Precision and Individualized Care

SBRT is rapidly becoming a cornerstone of modern cancer treatment, offering a non-invasive and highly targeted approach to tumor control. As technology advances and our understanding of cancer biology deepens, SBRT is likely to become even more precise and effective.

Ongoing research is focused on optimizing treatment protocols, minimizing side effects, and personalizing SBRT based on individual patient characteristics. By addressing the challenges of credentialing and dosimetric optimization, we can ensure that all patients have access to the highest quality SBRT treatment, regardless of where they receive care.

The insights into the rectal V3600cGy, highlights the complexity in prostate SBRT planning. As this treatment modality continues to be developed, open research for dose prescriptions and best practice will be necessary.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1016/j.ijrobp.2018.07.174, Alternate LINK

Title: Lung Sbrt Credentialing In The Canadian Lustre Randomized Trial

Subject: Cancer Research

Journal: International Journal of Radiation Oncology*Biology*Physics

Publisher: Elsevier BV

Authors: A. Swaminath, M. Wierzbicki, S. Parpia, V. Kundapur, J. Wright, T. Tsakiridis, K. Cline, C. Bucci, A.V. Louie, T.J. Whelan

Published: 2018-11-01

Everything You Need To Know

What is Stereotactic Body Radiation Therapy (SBRT) and how does it work?

Stereotactic Body Radiation Therapy (SBRT) is a cutting-edge cancer treatment that delivers high doses of radiation to tumors with extreme precision. This method minimizes harm to surrounding healthy tissues. This approach is particularly useful for patients with localized tumors, offering a non-invasive alternative to surgery or traditional radiation therapy. It's revolutionizing cancer care by focusing on accuracy and reducing side effects.

Why is Stereotactic Body Radiation Therapy (SBRT) considered an important advancement in cancer treatment?

SBRT is a significant advancement because of its precision in targeting tumors and minimizing damage to healthy tissues. The precision is particularly crucial for patients who may not be suitable for surgery or seek a less invasive option. The applications in lung and prostate cancer highlight its versatility and effectiveness in different cancer types. Proper credentialing, as demonstrated in the OCOG-LUSTRE trial, helps ensure consistent and high-quality treatment delivery, which is vital for patient safety and outcomes.

What role did credentialing play in the lung SBRT study?

The OCOG-LUSTRE trial, involving 15 Canadian centers, used a comprehensive credentialing process to ensure consistent SBRT delivery for lung cancer treatment. This process involved detailed surveys, phantom testing, and standardized contouring of tumors. The key aim was to maintain consistent quality across all centers involved. The success of the credentialing process in the OCOG-LUSTRE trial highlighted that despite centers passing phantom testing, there were still variations in contouring accuracy, especially concerning the brachial plexus and vessels, which underscores the importance of standardized training and quality assurance.

How is Stereotactic Body Radiation Therapy (SBRT) used to treat lung and prostate cancer?

In lung cancer, SBRT is used for both early-stage non-small cell lung cancer (NSCLC) and for managing local relapses after surgery. The credentialing process is vital to ensure precise and consistent treatment. In prostate cancer, SBRT offers an alternative to traditional radiation therapy, focusing on delivering high radiation doses to the tumor while protecting the rectum and nearby organs. This allows for effective tumor control while minimizing side effects such as rectal damage.

What does the future hold for Stereotactic Body Radiation Therapy (SBRT) in cancer treatment?

The future of SBRT involves balancing precision and individualized care, likely becoming even more effective as technology advances and understanding of cancer biology deepens. This points to a shift towards more personalized treatment plans tailored to each patient's specific needs, optimizing tumor control while minimizing side effects. The advancements in SBRT represent a move towards more sophisticated and effective cancer treatment strategies.